Newsbot

Lazard (LAZ) Beats Q4 Earnings and Revenue Estimates

Lazard (LAZ) delivered earnings and revenue surprises of +18.08% and +10.12%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Resilience, risk and recalibration: a year in review for sustainable investing

Despite evolving political views, regulatory recalibration and market volatility, sustainable investing has shown resilience rather than retreat over the past year, with growth shifting geographically and adaptation emerging as a critical new frontier for investors, according to Jaakko Kooroshy, global head sustainable investment research at LSEG.

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Companys issued and outstanding common shares. As previously disclosed, the Company’s Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026, however, following furthe...